MS Views and News Be empowered with MS views and news. CLICK HERE - - to SUBSCRIBE for The MS BEACON e-Newsletter

MS Views and News uses state-of-the-art technology to provide resources to the MS Community. Visit our MS learning channel on YouTube, to gain knowledge from hundreds of MS educational videos presented by MS Experts from across the USA. Click:

Within this blog you can find MS resources by viewing all showing below pertaining to thousands of MS articles, resources, event timing. Additionally, please visit our Social media platforms: Facebook, Twitter, and Instagram . Each providing important information for those affected by Multiple Sclerosis. * From the comfort of your home, you can join us for our VIRTUAL MS events. To learn more of these virtual events please subscribe here.

Disclaimer: 'MS Views and News' DOES NOT endorse any products or services found on this blog. It is up to you to seek advice from your healthcare provider. The intent of this blog is to provide information on various medical conditions, medications, treatments, for your personal knowledge and to keep you informed of current health-related issues. It is not a substitute for the advice of your physician. Should you or your family members have any specific medical problem, seek medical care promptly.


Saturday, May 9, 2020

Blogger @TrevisGleason muses on mixed messaging around face masks in the time of COVID-19

There have been plenty of mixed messages given about face masks during the COVID-19 pandemic — but masking up could be one small way we can all help out.

  By Trevis Gleason
For Life With Multiple Sclerosis
Last Updated: April 29, 2020

For people living with a chronic illness such as multiple sclerosis (MS), it can be difficult to find answers to the questions we have about the novel coronavirus. Specific advice about protecting ourselves from the virus, treatment with disease modifying therapy (DMT) during the pandemic, and more can be found across different nations’ MS societies’ websites. But even these sites vary in how much coverage they give to COVID-19.

The National MS Society, MS Ireland, and the MS Society of the UK, for example, all offer information on COVID-19 for people with MS, but they vary in the depth to which they cover the topic and link to other sources of information.

One area that seems to be rarely addressed, if ever, is specific advice on masks for people with MS.

Mixed Messaging Around Masks

The science of combatting SARS-CoV-2 (the virus behind COVID-19) is a fast-moving target. Different countries have quite different strategies for coping with the pandemic. Add that to the impression that science, politics, and the media seem to be more often colliding than collaborating, and you have a recipe for an underinformed (or worse, misinformed) public in this time of crisis.
The general use of masks for healthy individuals in the community (mass masking) is one such international divergence.

A recently published article in The Lancet called out the disparity. The World Health Organization (as of April 6) and Public Health England (as of April 23), for example, have not yet made recommendations for mass masking by healthy people.

CLICK to continue reading


This article is posted and shared by:  #MSViewsandNews

Friday, May 8, 2020


Supported by: Bristol Myers Squibb Foundation


Click HERE to Subscribe for the MS Beacon Newsletter


This article is posted and shared by:  #MSViewsandNews

Sunday, May 3, 2020

A Phase 2 Multicenter Study of Ublituximab, a Novel Glycoengineered anti-CD20 Monoclonal Antibody, in Patients With Relapsing Forms of Multiple Sclerosis

Click HERE to Subscribe for the MS Beacon Newsletter

2020  --- 
Background: Ublituximab, a novel monoclonal antibody (mAb) targeting a unique epitope on the CD20 antigen, is glycoengineered for enhanced B-cell targeting through antibody-dependent cellular cytotoxicity (ADCC). Greater ADCC may allow lower doses and shorter infusion times versus other anti-CD20 mAbs.

Objective: The objective was to determine optimal dose, infusion time, and activity of ublituximab in relapsing multiple sclerosis.

Methods: This is a phase 2, placebo-controlled study. Patients received three ublituximab infusions (150 mg over 1-4 hours on day 1 and 450-600 mg over 1-3 hours on day 15 and week 24) in six dosing cohorts. The primary endpoint was B-cell depletion.

Results: In all cohorts (N = 48), median B-cell depletion was >99% by week 4, maintained at weeks 24 and 48. Most common adverse events (AEs) were infusion-related reactions (all grade 1-2), with no apparent increased incidence at shorter infusion times. There were no AE-related discontinuations. At weeks 24 and 48, no T1 gadolinium-enhancing lesions (p = 0.003) and a 10.6% decrease in T2 lesion volume (p = 0.002) were detected. The annualized relapse rate was 0.07; 93% remained relapse free on study. Overall, 74% of patients had no evidence of disease activity (NEDA).

Conclusion: Ublituximab was safely infused as rapid as 1 hour, producing robust B-cell depletion and profound reductions in magnetic resonance imaging (MRI) activity and relapses.

Keywords: TG-1101; Ublituximab; gadolinium-enhancing lesions; magnetic resonance imaging; multiple sclerosis; relapse. 



This article is posted and shared by:  #MSViewsandNews